SciNeuro

SciNeuro Raises $53 million in Series B

SciNeuro has successfully raised $53 million in a Series B at a Undisclosed led by Chinese.

Company Overview

SciNeuro is a Biotechnology company headquartered in Shanghai China, founded in 2016 with 100+ employees.

SciNeuro secured funding for its pipeline of neurodegenerative disease therapies. The company focuses on developing treatments for Alzheimers Parkinsons and other neurological conditions using novel drug candidates.

Fundraising Details

• Amount Raised: $53 million
• Round Type: Series B
• Valuation: Undisclosed
• Date: 2025-11-18
• Investors: Chinese and international biotech investors

About SciNeuro

SciNeuro secured funding for its pipeline of neurodegenerative disease therapies. The company focuses on developing treatments for Alzheimers Parkinsons and other neurological conditions using novel drug candidates. The company is positioned in the Biotechnology sector, serving a growing market with innovative solutions.

Key Information

• Headquarters: Shanghai China
• Founded: 2016
• Team Size: 100+
• Industry: Biotechnology

What This Means

This funding round demonstrates strong investor confidence in SciNeuro's vision and execution. The capital will likely be used to:

• Scale Operations: Expand the team and operational capacity
• Product Development: Enhance existing products and develop new features
• Market Expansion: Enter new markets and strengthen presence in existing ones
• Technology Investment: Invest in infrastructure and technology capabilities

Industry Context

The Biotechnology sector continues to attract significant investment as companies innovate to meet evolving market demands. SciNeuro's successful fundraising reflects the strong fundamentals and growth potential in this space.

Valuation Milestone

Reaching Undisclosed marks an important milestone for SciNeuro, positioning the company among notable players in the Biotechnology industry.

Looking Ahead

With this new capital, SciNeuro is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotechnology space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.

This fundraising news was reported on 2025-11-18. For more information about SciNeuro, visit their headquarters at Shanghai China.